Biosceptre is the world leader in the utilisation of non-functioning P2X7 as a cancer target for therapeutic and diagnostic applications. The company has invested significant time and resources to investigate and characterise the non-functioning P2X7 receptor. This, combined with the development of antibodies that bind with high specificity, positions the company further down the drug development path than any potential competitors. Biosceptre has conducted a number of clinical trials and studies that demonstrate its therapeutics have significant potential to treat multiple cancer types. Biosceptre intends to develop its links with internationally renowned clinicians, academics and advisers to develop rapidly its product pipeline.